Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR88 | Q9GZN0 | 3/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.37 |
| ▸ | GCGR | P47871 | 1/20 | 0.37 |
| ▸ | GIPR | P48546 | 1/20 | 0.37 |
| ▸ | REN | P00797 | 4/20 | 0.36 |
| ▸ | BCL9 | O00512 | 2/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31258391 | 0.81 | BCL9 (0.47) | BCL9CTNNB1 | |
| SCHEMBL24872842 | 0.72 | BCL9 (0.70) | BCL9CTNNB1 | |
| SCHEMBL31258411 | 0.69 | REN (0.51) | OPRM1RENBCL9CTNNB1KCNH2 | |
| SCHEMBL31258378 | 0.68 | MEN1 (0.43) | OPRM1RENBCL9CTNNB1CTSD | |
| SCHEMBL31258376 | 0.67 | CTNNB1 (0.51) | BCL9CTNNB1 | |
| SCHEMBL31258399 | 0.66 | MC4R (0.51) | JAK3HDAC1 | |
| SCHEMBL4008398 | 0.66 | AKR1C3 (0.61) | JAK3HDAC2 | |
| SCHEMBL26302856 | 0.66 | AKR1C3 (0.61) | JAK3HDAC2 | |
| SCHEMBL4198203 | 0.64 | OPRM1 (0.62) | OPRM1CCR5KCNH2CTSD | |
| SCHEMBL3370759 | 0.64 | AGER (0.55) | OPRM1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391896-A1 | SMALL MOLECULE COMPOUND TARGETING BCL9/BETA-CATENIN INTERACTION | Nantong Jutai Biotech Co., Ltd. (CN) | 2024-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391896-A1 | SMALL MOLECULE COMPOUND TARGETING BCL9/BETA-CATENIN INTERACTION | BCL9, BCL9L, BCL2L11 | GPR88 2160/4885OPRM1 4604/4885PAX8 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.